US 12,220,410 B2
Antitumor composition
Naoto Ohi, Osaka (JP); Mitsuhiro Okuno, Osaka (JP); and Hideo Tanaka, Osaka (JP)
Assigned to OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
Appl. No. 17/429,531
Filed by OTSUKA PHARMACEUTICAL CO., LTD., Tokyo (JP)
PCT Filed Mar. 25, 2020, PCT No. PCT/JP2020/013454
§ 371(c)(1), (2) Date Aug. 9, 2021,
PCT Pub. No. WO2020/196665, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 2019-057029 (JP), filed on Mar. 25, 2019.
Prior Publication US 2022/0202794 A1, Jun. 30, 2022
Int. Cl. A61K 31/4412 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4412 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 7 Claims
 
1. An antitumor composition comprising:
synergistic amounts of the following antitumor agent (A), and
the following compound (B) or a salt thereof:
(A) at least one antitumor agent selected from the group consisting of bendamustine, decitabine, busulfan, lomustine, thiotepa, melphalan, cytarabine, venetoclax, ranimustine, ibrutinib, erlotinib, gefitinib, imatinib, axitinib, lapatinib, lenvatinib, afatinib, gilteritinib, 5-fluorouracil, cyclophosphamide, and rituximab;
(B) a compound or a salt thereof having the following formula (1):

OG Complex Work Unit Chemistry
wherein
R1 is a halogen atom or a C1-6 alkyl group, the C1-6 alkyl group being optionally substituted with one or more halogen atoms;
R2 is a hydrogen atom or a C1-6 alkyl group; and
m is an integer of 1 to 2, provided that when m is 2, R1 is the same or different.